Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
183/435
Matches for
“prognostic value”
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
…APRI had a significantly lower prognostic value versus biopsy, with a mean…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
…detect fibrosis, but their value as prognostic tests in chronic liver disease…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
…viral hepatitis, with a similar prognostic value as biopsy. The aim of…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
…We compared the 4-year prognostic value of combining FT-AT and…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
…The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…FibroTest has prognostic value for predicting overall survival in patients with type…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
…We compared the 5-year prognostic value of the FibroTest with biopsy…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
…stiffness and FibroTest values increased. Prognostic values of stiffness (P<.0001) and…
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
…To evaluate the 5-year prognostic value of liver stiffness, non-invasive…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
…The primary prognostic endpoint was the age-and sex-adjusted risk of…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
…The secondary aim was to provide an overview of the prognostic value…
-
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
…We investigated the prognostic role of the combined use of LS and…
-
Assessment of liver fibrosis: noninvasive means.
…be due to biopsy; the prognostic value of FibroTest is at least…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
Liver fibrosis markers in alcoholic liver disease. Review
…The evaluation of the degree of liver fibrosis is of great value…
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
…viral load, and alanine aminotransferase value. Only two biomarkers had several validations…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
…Baseline prognostic factors were combined using logistic regression analysis in a training…
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
…F4 using biopsy, and as prognostic markers of liver related mortality in…
-
Noninvasive diagnosis in alcohol-related liver disease.
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
…The staging of liver fibrosis still represents the most important prognostic problem…
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
…Use of general prognostic indices may help identify HCV patients at high…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
…progression and regression, with similar prognostic values. The aim was to estimate…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Liver biopsy: the best standard...when everything else fails.
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
…aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Biomarkers of liver fibrosis. Review
…The mean diagnostic value for the diagnosis of advanced fibrosis assessed using…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication
…The median AshTest value was 0.005 in controls, 0.05 in…
-
The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".
-
Non-invasive diagnosis and follow-up of portal hypertension.
…by a liver stiffness (LSM) value >15 kPa or clinical/biological/radiological…
-
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
…studies have demonstrated the predictive value and a better benefit-to-risk…
-
Noninvasive Assessment of Liver Fibrosis.
…detection of cirrhosis with likely prognostic value in this setting. Thus far…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review
…1) the presence of cirrhosis has prognostic relevance as it entails a…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
### Objective Studies have shown that patients with failing Fontan circulation may develop…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
…studies reporting the diagnostic and prognostic accuracy of the ELF test, FibroTest…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
…The predictive value of FT-AT was assessed using the area under…
-
The non-invasive assessment of hepatic fibrosis. Review
…one of the most relevant prognostic factors. The liver biopsy with the…
-
Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
### Background Non-invasive tests have been constructed and evaluated mainly for binary…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
…The co-primary study outcome was the negative predictive value (NPV) of…
-
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
…of cirrhosis and may have prognostic value in this setting. Guidelines are…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Key publication
### Background Haptoglobin bifucosylated tetra-antennary glycan have been identified in patients with…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
…The negative predictive value was 99.5% (95% CI 99.0-99…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable? Review
Liver biopsy, which was traditionally considered to be the gold standard for…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
### Objective There is a controversy about the performance of blood tests for…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…predictive value 80.3 per cent and negative predictive value 88.7…
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication
…The coprimary study outcome was the negative predictive value of LCR1-LCR2…
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
…time, and provide long-term prognostic information. Although clinically useful, current biomarker…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
…an estimate of the diagnostic value for fibrosis markers. Whether there is…
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication
…In this study, we examined the value of transient elastography in a…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
…evaluate whether Fibrotest^®^ adds diagnostic value relative to or in combination with…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.
Changes in the liver and bile ducts observed in patients diagnosed with…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
…This study aims, prospectively, to confirm the diagnostic value of PGAA and…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…decrease in the SteatoTest mean value from 0.66 at baseline to…
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
…peaks had an excellent accuracy value for the diagnosis of advanced fibrosis…
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
…have high five-year predictive value but with low AUROCs (0.60…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
…respectively. ### Conclusions FibroTest is of value in exclusion of patients with CHB…
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
Noninvasive assessment of portal hypertension in patients with cirrhosis. Review
…The radiological assessment of hyperkinetic syndrome probably has value but is still…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…
-
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.
### Background Previous research has shown variation in the effects of patient factors…
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Review
Chronic hepatitis B (CHB) infection is a major public health problem associated…
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
…these patients according to the value of FibroScan®, Fibrotest® or Fibrometer®. Hepatocellular…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…
-
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
Histological activity reflects the global assessment of basic necroinflammatory lesions and is…
-
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…
-
The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
The aim of this study was to investigate whether the non-invasive…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
### Aim To assess the diagnostic value of Fibrotest in comparison with liver…
-
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
### Background Noninvasive markers of liver fibrosis have not been extensively studied in…
-
Glycogenic hepatopathy. Review
### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
### Background One of the unmet needs in patients with type 2 diabetes…
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review. Review
Haemophilia is an entity, wherein the HCV infection rate is greater than…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fontan-associated liver disease (FALD) is a serious complication related to the…
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis…
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
…A cut-off at 0.80 had a 86% negative predictive value…
-
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
### Aim The objective of this study was to evaluate liver fibrosis using…
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
…at least two tests together will increase their diagnostic value still further.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
### Background In recent years noninvasive methods have been evaluated for the assessment…
-
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
…a fall in the FibroScan value. In conclusion, whatever the virological response…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Reproducibility of blood tests of liver fibrosis in clinical practice.
### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
### Background Mortality related to complications of cirrhosis is increasing in patients with…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
### Objectives Precise evaluation of the level of liver fibrosis is recommended in…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
### Background Our aim was to assess the natural history of liver fibrosis…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
…Statins decreased the low-density lipoprotein cholesterol mean value of 40%. All…
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Key publication
…an ELF value below 10.5 or a FibroTest value below 0…
-
[Prognosis assessment of alcoholic liver disease: how and why?]. Review
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
…a too low minimal elasticity value identifying not-reliable 2D-SWE results…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…DIACART and ACCoDiab cohorts (p-value for trend = 0.0009 and 0…
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
### Background This prospective, monocentric study was designed to assess the efficacy of…
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis
### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
### Background Preliminary data suggest that performance of non-invasive markers for liver…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review
Liver cirrhosis in Mexico is one of the most important causes of…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Showing the full result list. The page is server-rendered and not paginated.